Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 1 - 10 of about 182   

Articles published

AZN 4,524.50 +13.00 (0.29%)
price chart
Are AstraZeneca plc & GlaxoSmithKline plc A Sound Investment Right Now?
You may be safe if you invest in the pharma space now with a three-month investment horizon, although it must be noted that the shares of AstraZeneca (LSE: AZN) and Hikma Pharmaceuticals (LSE: HIK) - as well as those of a medical devices maker such as ...
Related articles »  
AstraZeneca plc Could Be Worth 5100p!
2014 has been a storming year for investors in AstraZeneca (LSE: AZN) (NYSE: AZN.US), with shares in the pharmaceutical giant gaining 28% since the turn of the year.
Related articles »  
Why AstraZeneca plc Should Beat The FTSE 100 This Year
Although the recovering FTSE 100 had a strong run in 2013 and turned in a gain of 14%, AstraZeneca (LSE: AZN) (NYSE: AZN.US) easily beat it with a 23% rise to end the year at close to �37 per share.
Related articles »  
A Scottish 'Yes' Can Boost ARM Holdings Plc, AstraZeneca plc, BHP Billiton plc ...
Pound Coins One big loser in the Scottish referendum debate is the pound. Sterling has fallen to a 10-month low as investors pull their money out of Britain ahead of next week's vote.
Eli Lilly Back In Alzheimer Space With AstraZeneca Deal
Eli Lilly and Co (LLY) has joined hands with AstraZeneca plc (ADR) (AZN) to speed up the development of the latter's investigational Alzheimer's drug in a $500 million deal.
AstraZeneca plc: AstraZeneca and Lilly announce alliance to develop and ...  The Wall Street Transcript
Eli Lilly amp; Co. agreed to pay AstraZeneca Plc as much...  Mynextfone
Related articles »  
Are You Too Late To Buy Shares In AstraZeneca plc?
2014 has been a super year for investors in AstraZeneca (LSE: AZN) (NYSE: AZN.US). Shares in the pharmaceutical giant have risen by 24% since the turn of the year, which is far better than the performance of the FTSE 100 over the same time period.
Related articles »  
Is GlaxoSmithKline plc's Opportunity AstraZeneca plc's Threat?
AstraZeneca Pharmaceutical companies are notoriously tricky businesses with massive reward potential; from patent legislation to pricing competitions, the road to medicinal gold is paved with an underlying risk that is beyond the grasp of most of us ...
AstraZeneca plc Earns �Neutral� Rating from Credit Suisse (AZN)
Shares of AstraZeneca plc (NYSE:AZN) traded down 0.19% on Tuesday, hitting $73.64. 2,306,318 shares of the company's stock traded hands.
Zacks Reaffirms "Neutral" Rating for AstraZeneca plc (AZN)  WKRB News
AstraZeneca plc (AZN) - Research Analysts' Recent Ratings Updates  Ticker Report
Related articles »  
AstraZeneca plc's Hold Rating Reiterated at Jefferies Group (AZN)
AstraZeneca plc logo AstraZeneca plc (LON:AZN)'s stock had its �hold� rating restated by stock analysts at Jefferies Group in a report issued on Monday.
Credit Suisse Reaffirms "Neutral" Rating for AstraZeneca plc (AZN)  Watch List News (press release)
Panmure Gordon Reaffirms "Hold" Rating for AstraZeneca plc (AZN)  Ticker Report
Related articles »  
The Benefits Of Investing In AstraZeneca plc
AstraZeneca has often been accused of lagging its industry rivals in terms of developing the next generation of sales-bursting products, a scenario made all the worse by exclusivity losses across a variety of products.